2126 Stock Overview
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
JW (Cayman) Therapeutics Co. Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.30 |
| 52 Week High | HK$2.72 |
| 52 Week Low | HK$1.19 |
| Beta | 2.13 |
| 1 Month Change | -2.26% |
| 3 Month Change | 4.84% |
| 1 Year Change | -50.00% |
| 3 Year Change | -89.80% |
| 5 Year Change | n/a |
| Change since IPO | -94.09% |
Recent News & Updates
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25Recent updates
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb
May 10Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
May 03JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?
Feb 03Shareholder Returns
| 2126 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -11.6% | -3.0% | -1.9% |
| 1Y | -50.0% | -6.4% | 18.4% |
Return vs Industry: 2126 underperformed the Hong Kong Biotechs industry which returned -6.4% over the past year.
Return vs Market: 2126 underperformed the Hong Kong Market which returned 18.4% over the past year.
Price Volatility
| 2126 volatility | |
|---|---|
| 2126 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.8% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2126 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2126's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 323 | Min Liu | www.jwtherapeutics.com |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary
| 2126 fundamental statistics | |
|---|---|
| Market cap | HK$525.95m |
| Earnings (TTM) | -HK$669.67m |
| Revenue (TTM) | HK$184.45m |
2.9x
P/S Ratio-0.8x
P/E RatioIs 2126 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2126 income statement (TTM) | |
|---|---|
| Revenue | CN¥172.93m |
| Cost of Revenue | CN¥85.78m |
| Gross Profit | CN¥87.15m |
| Other Expenses | CN¥715.00m |
| Earnings | -CN¥627.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.55 |
| Gross Margin | 50.40% |
| Net Profit Margin | -363.06% |
| Debt/Equity Ratio | 22.5% |
How did 2126 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 02:04 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
JW (Cayman) Therapeutics Co. Ltd is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Tony Ren | CLSA |